Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials

Structure Therapeutics Inc.

Amended and restated Sales Agreement with Leerink Partners and Cantor Fitzgerald to remove aggregate offering limit and filed prospectus supplement increasing ATM by $150M to $400M.
Aleniglipron Phase 2 ACCESS II achieved placebo-adjusted weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks.
Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026; received $100M upfront license fee in Q1.
FDA provided positive end-of-Phase 2 feedback; Phase 3 program for aleniglipron expected to initiate in Q3 2026.
Net loss for Q1 2026 was $76.0 million, including $11.6 million non-cash share-based compensation.

item 1.01 item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Structure Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Structure Therapeutics Inc. amended Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. (effective 2026-05-07).

Action: amendment
Agreement: atm program
Counterparty: Leerink Partners LLC and Cantor Fitzgerald & Co.
Effective: 2026-05-07

Exact text from the filing

On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share.

View on SEC.gov

Browse all earnings releases →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-057226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.